Flavia Jacqueline Almeida

Dr. Flavia Jacqueline Almeida

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2019 in Jornal de Pediatria
Verified
Journal Article
Open access
FAFlavia Jacqueline Almeida
Flavia Jacqueline Almeida
CKCristiane Kochi
Cristiane Kochi
MSMarco Aurelio Palazzi Safadi
Marco Aurelio Palazzi Safadi
Weight and height growth impairment is one of the most frequent manifestations in HIV-infected children and may be the first sign of disease, being considered a marker of disease progression and an independent risk factor for death. The aim of this review is to evaluate the influence of antiretroviral therapy on the growth pattern of children and adolescents living with HIV/AIDS. A non-systematic review was carried out in the PubMed database, with the terms "HIV", "Weight and height growth", "ART" and "children". The most relevant publications were selected. Antiretroviral therapy has significantly reduced morbidity and mortality in HIV-infected children and is clearly associated with recovery of weight and height-for-age Z-scores, especially when started early, in the asymptomatic child still without weight-height impairment. Therapeutic strategies involving the GH/IGF-1 axis, especially for children with growth impairment, are still being studied. HIV-infected children show early weight-height impairment; antiretroviral therapy improves the anthropometric profile of these children.

21 March 2009 in Jornal de Pediatria
Verified
Journal Article
Open access
FAFlavia Jacqueline Almeida
Flavia Jacqueline Almeida
EBEitan N. Berezin
Eitan N. Berezin
RRRosângela Rodrigues
Rosângela Rodrigues
MSMarco Aurelio Palazzi Safadi
Marco Aurelio Palazzi Safadi
MAMariana V. Arnoni
Mariana V. Arnoni
LBLuis F. M. Brígido
Luis F. M. Brígido
To evaluate genotyping and subtyping in antiretroviral (ARV) naïve and experienced children, as well as drug resistance profiles through genotyping in these children.

27 October 2019 in Jornal de Pediatria
Verified
Journal Article
Open access
LCLuis Eduardo Calliari
Luis Eduardo Calliari
FAFlavia Jacqueline Almeida
Flavia Jacqueline Almeida
RNRenata Maria Noronha
Renata Maria Noronha
The association between diabetes mellitus and infections is very common. These infections, even when mild, interfere with blood glucose control. The aim of this review is to describe infections that occur in children and adolescents with DM, as well as to provide recommendations on glycemia management during these episodes. A non-systematic review was carried out in the PubMed database, using the terms "diabetes mellitus," "infection," "children," and "adolescents." The most relevant publications were selected. In addition to the usual community diseases, some infections may occur predominantly in diabetic patients, especially when there is inadequate glycemic control, and common infections can be more severe in these patients. Alterations caused by the disease itself and the immune response are responsible for the risk of higher frequency and severity of infections. During infections, an increase in blood glucose occurs and usually an increase in insulin dose is required. Pediatric patients with diabetes have some immune system disorders that, when associated with high glycemia, increase the risk of infections and their severity, and should be promptly identified and treated. The presence of an infectious condition, in turn, raises blood glucose and increases the risk of decompensation, and pediatricians should be cautioned to intensify monitoring and insulin therapy, and to avoid the risk of DKA. It should also be noted that many infections are preventable and can be avoided with adequate vaccine coverage.

29 November 2024 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
FAFlavia Jacqueline Almeida
Flavia Jacqueline Almeida
JPJuliana Torres Pacheco
Juliana Torres Pacheco
CFCamila Giuliana Almeida Farias
Camila Giuliana Almeida Farias
SMSamantha Faria de Matos
Samantha Faria de Matos
CMCamila Ohomoto de Morais
Camila Ohomoto de Morais
MSMarco Aurélio Palazzi Sáfadi
Marco Aurélio Palazzi Sáfadi

15 December 2022 in IJID Regions
Verified
Journal Article
Open access
DJDaniel Jarovsky
Daniel Jarovsky
GFGiuliana de Freitas Fongaro
Giuliana de Freitas Fongaro
RZRenata Mazzotti Zampol
Renata Mazzotti Zampol
TOThales Araújo de Oliveira
Thales Araújo de Oliveira
CFCamila Giuliana Almeida Farias
Camila Giuliana Almeida Farias
MSMarco Aurelio Palazzi Safadi
Marco Aurelio Palazzi Safadi
In 2020, Brazil became the epicentre of the coronavirus disease (COVID-19) pandemic in Latin America, resulting in an unparalleled health catastrophe. Nevertheless, comprehensive clinical reports in Brazilian children are not available. This retrospective, hospital-based, active surveillance study was performed to identify paediatric patients with COVID-19 who presented at a private academic medical centre in a large urban area between March 2020 and March 2021. Clinical and demographic information was analysed for those requiring hospitalization, those with severe illness and those with clinical syndromes. In total, 964 symptomatic cases were evaluated; of these, 17.7% required hospitalization, and 27.5% of hospitalized cases were classified as severe/critical. Acute bronchiolitis and pneumonia were the most common causes of hospitalization among the severe cases. Twenty-seven hospitalized children fulfilled the diagnostic criteria for multi-system inflammatory syndrome (median age 29 months; 85.2% cases were non-severe). A significant co-existing condition was present in 29% of hospitalized children. The risk of hospitalization was higher in children with at least one comorbidity, children aged <2 years and obese children. Increased risk of severe disease was described among those with leukopenia, leukocytosis or any significant comorbidity. No deaths occurred among the study population. Although most children with COVID-19 experienced mild disease, and no deaths occurred among the study population, a significant proportion of cases required hospitalization and developed severe illness. Obesity, young age, underlying comorbidity, leukopenia and leukocytosis were risk factors for hospitalization or severe disease.

1 December 2012 in The Pediatric Infectious Disease Journal
Verified
Journal Article
Closed access
FAFlavia Jacqueline Almeida
Flavia Jacqueline Almeida
RRRosangela Rodrigues
Rosangela Rodrigues
MZMayra Simioni Msc Zaparoli
Mayra Simioni Msc Zaparoli
EBEitan Naaman Berezin
Eitan Naaman Berezin
MSMarco Aurelio Palazzi Safadi
Marco Aurelio Palazzi Safadi
LBLuis Fernando de Macedo Brígido
Luis Fernando de Macedo Brígido
HIV drug resistance genotype testing, performed on 39 HIV-infected treatment-naive children from 2000 to 2011, identified 5 children (12.8%) with drug resistance mutations: 5.3% to nucleoside reverse transcriptase inhibitors, 5.3% to nonnucleoside reverse transcriptase inhibitors and 7.7% to protease inhibitors. There was a trend for increasing prevalence of drug resistance mutations during the 11-year study period.